{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T01:50:21Z","timestamp":1782870621271,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In haemophilia, recurrent joint bleeding often results in joint destruction, which in turn leads to reduced physical activity (PA) and decreased quality of life (QOL). While maintaining high PA levels is important in the care of people with haemophilia (PwH), it remains unclear whether PwH without joint disease can maintain adequate activity levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This descriptive cross-sectional study sought to compare moderate-to-vigorous physical activity (MVPA) levels among 19 PwH with haemophilic arthropathy (HA), 12 PwH without HA, and 15 non-PwH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 46 males wore a triaxial accelerometer (wGT3X-BT, ActiGraph) during daily activities for seven consecutive days. A bout of MVPA was defined as at least 10 consecutive minutes of moderate-intensity or higher activity. MVPA was expressed as the percentage of the total wear time spent in MVPA, and the total number of MVPA bouts was also recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Both PwH groups demonstrated significantly lower MVPA percentages and fewer MVPA bouts than the controls (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). No MVPA bouts were recorded among 52.6% of PwH with HA versus 25% of PwH without HA. No significant differences were observed in sedentary or light activity between the PwH groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PA levels were significantly reduced in PwH, regardless of joint status, suggesting that factors beyond joint damage, such as fear of bleeding or behavioural avoidance, may play a role. These findings highlight the need for individualized, evidence-based interventions to safely promote physical activity and improve long-term health outcomes in PwH.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12959-026-00869-2","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T16:14:24Z","timestamp":1778170464000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Physical activity patterns in people with haemophilia with and without arthropathy: a cross-sectional study using wearable sensors"],"prefix":"10.1186","volume":"24","author":[{"given":"Yuya","family":"Mawarikado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midori","family":"Shima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asuka","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryohei","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Tatsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhiro","family":"Soeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Seriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Inagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Kido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Nogami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"869_CR1","doi-asserted-by":"crossref","unstructured":"Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26:1\u2013158.","DOI":"10.1111\/hae.14046"},{"key":"869_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.15256\/joc.2011.1.2","volume":"1","author":"K Knobe","year":"2011","unstructured":"Knobe K, Berntorp E. Haemophilia and joint disease: pathophysiology, evaluation, and management. J Comorb. 2011;1:51\u20139.","journal-title":"J Comorb"},{"key":"869_CR3","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/j.1365-2516.2011.02567.x","volume":"17","author":"RR Riley","year":"2011","unstructured":"Riley RR, Witkop M, Hellman E, Akins S. Assessment and management of pain in haemophilia patients. Haemophilia. 2011;17:839\u201345.","journal-title":"Haemophilia"},{"key":"869_CR4","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1111\/hae.13214","volume":"23","author":"M Witkop","year":"2017","unstructured":"Witkop M, Neff A, Buckner TW, Wang M, Batt K, Kessler CM, et al. Self-reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the pain, functional impairment, and quality of life (P-FiQ) study. Haemophilia. 2017;23:556\u201365.","journal-title":"Haemophilia"},{"key":"869_CR5","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1007\/s00508-020-01798-4","volume":"133","author":"W Stromer","year":"2021","unstructured":"Stromer W, Pabinger I, Ay C, Crevenna R, Donnerer J, Feistritzer C, et al. Pain management in hemophilia: expert recommendations. Wien Klin Wochenschr. 2021;133:1042\u201356.","journal-title":"Wien Klin Wochenschr"},{"key":"869_CR6","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1182\/blood-2016-02-683169","volume":"129","author":"MJ Manco-Johnson","year":"2017","unstructured":"Manco-Johnson MJ, Soucie JM, Gill JC. Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project. Blood. 2017;129:2368\u201374.","journal-title":"Blood"},{"key":"869_CR7","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1703068","volume":"377","author":"J Oldenburg","year":"2017","unstructured":"Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, et al. Emicizumab prophylaxis in hemophilia a with inhibitors. N Engl J Med. 2017;377:809\u201318.","journal-title":"N Engl J Med"},{"key":"869_CR8","first-page":"CD011180","volume":"12","author":"K Strike","year":"2016","unstructured":"Strike K, Mulder K, Michael R. Exercise for haemophilia. Cochrane Database Syst Rev. 2016;12:CD011180.","journal-title":"Cochrane Database Syst Rev"},{"key":"869_CR9","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1093\/ptj\/pzaa106","volume":"100","author":"J Calatayud","year":"2020","unstructured":"Calatayud J, P\u00e9rez-Alenda S, Carrasco JJ, Cruz-Montecinos C, Andersen LL, Bonanad S, et al. Safety and Effectiveness of Progressive Moderate-to-Vigorous Intensity Elastic Resistance Training on Physical Function and Pain in People With Hemophilia. Phys Ther. 2020;100:1985\u201396.","journal-title":"Phys Ther"},{"key":"869_CR10","volume-title":"WHO guidelines on physical activity and sedentary behaviour","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. WHO guidelines on physical activity and sedentary behaviour. Geneva: World Health Organization; 2020."},{"key":"869_CR11","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/hae.12118","volume":"19","author":"C Negrier","year":"2013","unstructured":"Negrier C, Seuser A, Forsyth A, Lobet S, Llinas A, Rosas M, et al. The benefits of exercise for patients with haemophilia and recommendations for safe and effective physical activity. Haemophilia. 2013;19:487\u201398.","journal-title":"Haemophilia"},{"key":"869_CR12","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/hae.14282","volume":"27","author":"M Kennedy","year":"2021","unstructured":"Kennedy M, O\u2019Gorman P, Monaghan A, Lavin M, O\u2019Mahony B, O\u2019Connell NM, et al. A systematic review of physical activity in people with haemophilia and its relationship with bleeding phenotype and treatment regimen. Haemophilia. 2021;27:544\u201362.","journal-title":"Haemophilia"},{"key":"869_CR13","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/hae.14987","volume":"30","author":"Y Mawarikado","year":"2024","unstructured":"Mawarikado Y, Sakata A, Inagaki Y, Harada S, Tatsumi K, Matsumoto N, et al. Force-sensing treadmill gait analysis system can detect gait abnormalities in haemophilia patients without arthropathy. Haemophilia. 2024;30:780\u201390.","journal-title":"Haemophilia"},{"key":"869_CR14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2106\/00004623-197759030-00001","volume":"59","author":"WD Arnold","year":"1977","unstructured":"Arnold WD, Hilgartner MW. Hemophilic arthropathy. Current concepts of pathogenesis and management. J Bone Joint Surg Am. 1977;59:287\u2013305.","journal-title":"J Bone Joint Surg Am"},{"key":"869_CR15","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jsams.2011.04.003","volume":"14","author":"JE Sasaki","year":"2011","unstructured":"Sasaki JE, John D, Freedson PS. Validation and comparison of ActiGraph activity monitors. J Sci Med Sport. 2011;14:411\u20136.","journal-title":"J Sci Med Sport"},{"key":"869_CR16","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1161\/CIRCULATIONAHA.107.185649","volume":"116","author":"WL Haskell","year":"2007","unstructured":"Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, Franklin BA, et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Circulation. 2007;116:1081\u201393.","journal-title":"Circulation"},{"key":"869_CR17","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1001\/jama.2018.14854","volume":"320","author":"KL Piercy","year":"2018","unstructured":"Piercy KL, Troiano RP, Ballard RM, Carlson SA, Fulton JE, Galuska DA, et al. The physical activity guidelines for Americans. JAMA. 2018;320:2020\u20138.","journal-title":"JAMA"},{"key":"869_CR18","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/ageing\/afz046","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruy\u00e8re O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:601.","journal-title":"Age Ageing"},{"key":"869_CR19","doi-asserted-by":"publisher","first-page":"205510292110399","DOI":"10.1177\/20551029211039920","volume":"8","author":"S B\u00e9rub\u00e9","year":"2021","unstructured":"B\u00e9rub\u00e9 S, Ogez D, Aramideh J, Amesse C, Bourque CJ, Longpr\u00e9 C, et al. It\u2019s difficult to say no: development of a parenting booklet about physical activity restrictions and recommendations in pediatric hemophilia. Health Psychol Open. 2021;8:20551029211039920.","journal-title":"Health Psychol Open"},{"key":"869_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2147\/JBM.S84848","volume":"7","author":"M Goto","year":"2016","unstructured":"Goto M, Takedani H, Yokota K, Haga N. Strategies to encourage physical activity in patients with hemophilia to improve quality of life. J Blood Med. 2016;7:85\u201398.","journal-title":"J Blood Med"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-026-00869-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-026-00869-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-026-00869-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T01:40:14Z","timestamp":1782870014000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12959-026-00869-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["869"],"URL":"https:\/\/doi.org\/10.1186\/s12959-026-00869-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8217815\/v1","asserted-by":"object"}]},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"27 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants were given a clear and comprehensive explanation of the study and its purpose in accordance with the Declaration of Helsinki. The participants subsequently provided signed informed consent. Ethical approval for the study was obtained from both Nara Medical University (ID: 1979) and Chugai Ethics Committees (ID: E20019).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No identifiable subject information is provided in the manuscript, figures, or tables.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"YM: Is a member of the Medicinal Biology of Thrombosis and Hemostasis, established by Nara Medical University and Chugai Pharmaceutical Co., Ltd.; has received personal fees from Bayer AG. MS: Is a member of the Medicinal Biology of Thrombosis and Hemostasis, established by Nara Medical University and Chugai Pharmaceutical Co., Ltd.; has received research funding from Chugai Pharmaceutical Co., Ltd., CSL Behring, and Takeda; has received honoraria from Bayer, Chugai Pharmaceutical Co., Ltd., CSL Behring, Fujimoto Seiyaku, Sanofi, Novo Nordisk, Pfizer, and Takeda; holds patents with Chugai Pharmaceutical Co., Ltd.; and has served on data safety monitoring boards or advisory boards for Chugai Pharmaceutical Co., Ltd., Fujimoto Seiyaku, KYORIN Pharmaceutical Co., Ltd., Novo Nordisk, and Pfizer. NS: Has received honoraria from Bayer, Chugai Pharmaceutical Co., Ltd., CSL Behring, Japan Blood Products Organization, KM Biologics, Novo Nordisk, Pfizer, Sanofi, and Takeda. NM: Is a member of the Medicinal Biology of Thrombosis and Hemostasis, established by Nara Medical University and Chugai Pharmaceutical Co., Ltd.; owns stock in Chugai Pharmaceutical Co., Ltd. AS: Is a member of the Medicinal Biology of Thrombosis and Hemostasis, established by Nara Medical University and Chugai Pharmaceutical Co., Ltd. RK: Is a member of the Medicinal Biology of Thrombosis and Hemostasis, established by Nara Medical University and Chugai Pharmaceutical Co., Ltd. KT: Is a member of the Medicinal Biology of Thrombosis and Hemostasis, established by Nara Medical University and Chugai Pharmaceutical Co., Ltd.; has received personal fees from Novo Nordisk A\/S. TS: Is a member of the Medicinal Biology of Thrombosis and Hemostasis, established by Nara Medical University and Chugai Pharmaceutical Co., Ltd. SH: Is a member of the Medicinal Biology of Thrombosis and Hemostasis, established by Nara Medical University and Chugai Pharmaceutical Co., Ltd.; owns stock in Chugai Pharmaceutical Co., Ltd. NS: Reports no conflicts of interest. YI: Has received specific clinical trial funding from MediaMart Co., Ltd.; has received research funding from Chugai Pharmaceutical Co., Ltd., Johnson & Johnson K.K., KM Biologics, Olympus Terumo Biomaterials Corp., and Zimmer Biomet; has received honoraria from Asahi Kasei Pharma Corporation, Bayer Yakuhin Ltd., Chugai Pharmaceutical Co., Ltd., CSL Behring, Healios K.K., Hisamitsu Pharmaceutical Co., Johnson & Johnson K.K., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Novo Nordisk Pharma Ltd., Sanofi K.K., and Takeda Pharmaceutical Co., Ltd.; and serves as a medical advisor for Chugai Pharmaceutical Co., Ltd. and KM Biologics. AK: Has received grants or research support from Chugai Pharmaceutical Co., Ltd. KN: Is a member of the Medicinal Biology of Thrombosis and Hemostasis, established by Nara Medical University and Chugai Pharmaceutical Co., Ltd.; has received grants, personal fees, and nonfinancial support from Chugai Pharmaceutical Co., Ltd.; personal fees from F. Hoffmann-La Roche Ltd.; has received grants, personal fees, and nonfinancial support from Sysmex Co.; has received grants and personal fees from Takeda Pharmaceutical Co.; has received grants and personal fees from Sanofi S.A.; has received personal fees from CSL Behring Co.; has received grants and personal fees from KM Biologics Co.; grants and personal fees from Novo Nordisk A\/S; has received grants and personal fees from Bayer AG; has received grants and personal fees from Bioverativ Inc.; has received grants and personal fees from Shire Plc; and is a coinventor of a patent related to an anti-FIXa\/FX bispecific antibody.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}